Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients

References

• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118
   PubMed Web of Science ®Google Scholar
• Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, Cattaneo D. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007; 8: 1127–1141
   PubMed Web of Science ®Google Scholar
• Basu NK, Kole L, Kubota S, Owens IS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metabolism and Disposition 2004; 32: 768–773
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metabolism and Disposition 2004; 32: 775–778
   PubMed Web of Science ®Google Scholar
• Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metabolism and Disposition 2006; 34: 1539–1545
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679–685
   PubMedGoogle Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics 1998; 34: 429–455
   PubMed Web of Science ®Google Scholar
• Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical Cancer Research 2005; 11: 1226–1236
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang WX, Yu ZC, Cai WM. Determination of mycophenolic acid (MPA) and its acyl and phenol glucuronide metabolites simultaneously in human plasma by a simplified HPLC method. Analytical Letters 2007; 40: 2465–2475
   Web of Science ®Google Scholar
• Coffman BL, Kearney WR, Green MD, Lowery RG, Tephly TR. Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy. Molecular Pharmacology 2001; 59: 1464–1469
   PubMed Web of Science ®Google Scholar
• Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenetics and Genomics 2007; 17: 321–330
   PubMed Web of Science ®Google Scholar
• Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, Levy RD. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Therapeutic Drug Monitoring 2002; 24: 310–314
   PubMed Web of Science ®Google Scholar
• Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, Von Moltke LL, Perussed L, Guillemette C. Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14: 501–515
   PubMedGoogle Scholar
• Hesselink DA, Van Hest RM, Mathot RA, Bonthuis F, Weimar W, De Bruin RW, Van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. American Journal of Transplantation 2005; 5: 987–994
   PubMed Web of Science ®Google Scholar
• Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metabolism and Disposition 2003; 31: 677–680
   PubMed Web of Science ®Google Scholar
• Innocenti F, Liu W, Chen P, Desai AA, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenetics and Genomics 2005; 15: 295–301
   PubMed Web of Science ®Google Scholar
• Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–184
   PubMedGoogle Scholar
• Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. European Journal of Clinical Pharmacology 2007; 63: 279–288
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. Journal of Pharmacology and Experimental Therapeutics 2004; 309: 1029–1035
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients. Journal of Clinical Pharmacology 2003a; 43: 866–880
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics 2005; 78: 351–361
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Therapeutic Drug Monitoring 2003b; 25: 609–622
   PubMed Web of Science ®Google Scholar
• Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clinical Pharmacology and Therapeutics 2007; 81: 392–400
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074–1084
   PubMed Web of Science ®Google Scholar
• Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clinical Pharmacology and Therapeutics 2006; 80: 468–476
   PubMed Web of Science ®Google Scholar
• Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics Journal 2006; 6: 63–75
   PubMed Web of Science ®Google Scholar
• Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Therapeutic Drug Monitoring 2000; 22: 14–19
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. American Journal of Transplantation 2003; 3: 534–542
   PubMed Web of Science ®Google Scholar
• Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. British Journal of Pharmacology 2001a; 132: 1027–1034
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, Oellerich M, Armstrong VW. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proceeding 2001b; 33: 1080–1081
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical Pharmacokinetics 2007; 46: 13–58
   PubMed Web of Science ®Google Scholar
• Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (/ABCC2): Its impact on drug disposition. Advanced Drug Delivery Reviews 2002; 54: 1311–1331
   PubMed Web of Science ®Google Scholar
• Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Therapeutic Drug Monitoring 2001; 23: 119–128
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14: 329–332
   PubMedGoogle Scholar
• Zhang W, Liu W, Innocenti F, Ratain MJ. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. Public Library of Science ONE 2007; 2: e396
   Google Scholar